Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

Tom Loosli; Carolyn Bolton‐Moore; Lydia Buzaalirwa; Helen Byakwaga; İpek Çelikağ; Cleophas Chimbetete; Peter Vanes Ebasone; Jennifer Giandhari; Nuri Han; Jacqueline Huwa; Charles Kasozi; Adolphe Mafoua; Eugène Messou; Albert Minga; Guy Muula; Winnie Muyindike; Arcel Christ Massamba Ndala; Mamatha Sauermann; Aggrey Semeere; Lavanya Singh; Roger D. Kouyos; Richard Lessells; Matthias Egger

doi:10.1093/cid/ciaf204

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Loosli et al. (2025) studied this question.

synapsesocial.com/papers/6a9f6540303f235a3815d988 https://doi.org/10.1093/cid/ciaf204

View Full Paper

Ask AI

Bookmark

Share

Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

Ask about this paper

Abstract

Discussion

Cite This Study

Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading